Creighton S, Miller R, Edwards S, Copas A, French P
Department of Genitourinary Medicine, Camden Primary Care Trust, Mortimer Market Centre, Mortimer Market, off Capper Street, London WC1E 6AU, UK.
Int J STD AIDS. 2005 May;16(5):362-4. doi: 10.1258/0956462053888907.
Asymptomatic hyperuricaemia is associated with ritonavir therapy, but gout has rarely been reported. We present a retrospective cohort study of 1825 HIV-positive patients seen at one inner London HIV clinic over a two-year period. In all, 18 patients had gout, of whom 15 were receiving antiretroviral therapy. Seven had predisposing risk factors for gout (e.g. pyrazinamide therapy, haematological malignancy). Of the remaining 11 patients, two were on no medication and eight (73%) were receiving ritonavir as a boosted protease inhibitor (PI). By comparison, 11% of HIV-positive patients without gout were receiving ritonavir (odds ratio = 22; confidence interval = 5-104). Seven of the 18 patients had documented features of lipodystrophy and dyslipidaemia. Gout was seen in patients with known risk factors for gout or who were receiving ritonavir as a boosted PI and who also had lipodystrophy.
无症状高尿酸血症与利托那韦治疗相关，但痛风鲜有报道。我们对伦敦市中心一家艾滋病诊所两年内诊治的1825例HIV阳性患者进行了一项回顾性队列研究。共有18例患者患有痛风，其中15例正在接受抗逆转录病毒治疗。7例有痛风的易感风险因素（如吡嗪酰胺治疗、血液系统恶性肿瘤）。在其余11例患者中，2例未用药，8例（73%）正在接受利托那韦作为增效蛋白酶抑制剂（PI）治疗。相比之下，无痛风的HIV阳性患者中11%正在接受利托那韦治疗（优势比=22；置信区间=5-104）。18例患者中有7例有脂肪代谢障碍和血脂异常的记录特征。痛风见于有已知痛风风险因素或正在接受利托那韦作为增效PI治疗且同时有脂肪代谢障碍的患者。
